Sun Pharma and Samsung BioLogics announced a strategic long-term manufacturing agreement for Tildrakizumab used for treatment of psoriasis.

The agreement was entered into by Sun Pharma's wholly- owned subsidiary and Samsung BioLogics. Sun Pharma has appointed Samsung BioLogics to manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis.

The approximate value of the contract will be USD 55.5 million, while the other financial details of the agreement are confidential. The agreement was signed at Samsung BioLogics' headquarter in Incheon, South Korea.

Filings for this novel investigational biologic has been accepted for review by the US Food and Drug Administration (FDA) (May 2017) and the European Medicines Agency (EMA) (March 2017).

As a joint venture between Samsung affiliate companies and Quintiles Transnational Corp., Samsung BioLogics aims to become a global leader in the biopharmaceutical manufacturing industry.

Dr. TH Kim, President and CEO of Samsung BioLogics stated thet Samsung BioLogics is pleased to join hands with Sun Pharma and is looking forward to delivering best-in-class manufacturing services with global quality standards. The collaboration with Sun Pharma is an important milestone for Samsung as it is a testament of our ability to provide reliable supply through its GMP-certified manufacturing facility to pharmaceutical companies, which aim to expand their global market.